Phase II
For a look at what’s going on with kids and COVID-19, and related stories, continue reading.
Adagio cited three recent independent, in vitro studies showing that ADG20, which is currently undergoing Phase II/III clinical trials, has neutralization activity against Omicron.
Biopharma and life sciences companies from across the globe provide updates to their businesses and pipelines.
PCN-101 was recently awarded Investigational New Drug (IND) status by the U.S. Food and Drug Administration. It’s a for treating the patients with treatment resistant depression.
Pardes is funneling the funds into financing the next stage of clinical trials and commercial production of its lead oral antiviral drug, PBI-0451, for the treatment and prevention of SARS-CoV-2 infections.
According to the Environmental Litigation Group, P.C., approximately 37.5% of all occupational lung cancer cases are related to occupational asbestos exposure.
Amicus announced that it is halting its CLN6 Batten disease gene therapy program after studies failed to achieve consistent results.
U.K.-based Clarivate Plc has identified seven late-stage assets or recently-approved drugs that could hit the billion-dollar per year mark within five years.
The 2022 virtual J.P. Morgan Healthcare Conference got off to a roaring start Monday with deal announcements and plans to drive biopharma companies through the coming year.
Allogene announced that the chromosomal abnormality was not detected in any manufactured AlloCAR T product or any patient treated with the same lot of drugs.
PRESS RELEASES